Navigation Links
Abbott Presents Results of Clinical Studies Evaluating Its Investigational Treatment for Advanced Parkinson's Disease
Date:6/18/2012

DUBLIN, June 18, 2012 /PRNewswire/ -- Today Abbott (NYSE: ABT) announced results from five abstracts evaluating levodopa-carbidopa intestinal gel (LCIG), its investigational compound for advanced Parkinson's disease. The abstracts include the results from the second interim analysis of a long-term safety and tolerability trial, as well as secondary endpoint analyses from the Phase 3 pivotal trial. All of the abstracts were presented at The 16th International Congress of Parkinson's Disease and Movement Disorders, June 17-21 in Dublin, Ireland.

LCIG is currently approved in 40 countries. In the U.S., LCIG is an investigational therapy that is currently being evaluated in patients with advanced Parkinson's disease in additional Phase 3 clinical trials. In these trials, levodopa-carbidopa is administered in gel form, directly into the small intestine via a procedurally-implanted tube connected to a portable pump that delivers continuous supply of LCIG during awake hours.

Long-Term Safety and Tolerability
In a 54 week open-label safety and tolerability study of 354 patients with advanced Parkinson's disease, the primary endpoint of safety showed adverse events (AEs) were mostly mild to moderate, were generally associated with the Percutaneous Endoscopic Gastrostomy (PEG) tube placement procedure and its complications, were transient, and resolved over time.

In the secondary endpoint analysis from the open-label study, patients experienced an average daily "off" time of 6.7 hours, and 7.7 hours of "on" time without troublesome dyskinesia at baseline. "Off" time refers to periods of poor mobility, slowness and stiffness experienced by patients with Parkinson's disease, while "on" time refers to periods of good motor symptom control. At week 54, mean daily "off" time had decreased an average of 4.5 h
'/>"/>

SOURCE Abbott
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Grant & Eisenhofer Represents Lead Whistleblower in Historic $1.6 Billion Settlement with Abbott Laboratories Over Off-Label Marketing of Antiepileptic Medication Depakote
2. Abbott Announces Collaboration with Syngene to Open First Nutrition R&D Center in India
3. Frost & Sullivan: Developing Integration Capabilities Presents a Real Opportunity for Vendors in the European CIS Market
4. This Week: UBM Canon Presents an Online Event and Conference Dedicated to Emerging Trends in Medical Device Outsourcing/Contract Manufacturing
5. Berg Pharma presents at ASCO, poised to lead field in cancer metabolism with Phase II trials of BPM 31510
6. Lexicon Presents Data Regarding the Mechanism of Action and Safety of LX4211 at American Diabetes Association Meeting
7. Vanda Pharmaceuticals Inc. Presents Scientific Posters at Society for Research on Biological Rhythms (SRBR) Annual Meeting
8. Boehringer Ingelheim Presents First Data for Tiotropium in Adolescents with Moderate Persistent Asthma
9. Lilly Diabetes Presents Phase II Blood Pressure and Heart Rate Data on Investigational GLP-1 Analog Candidate, Dulaglutide, in Patients with Type 2 Diabetes at the 27th American Society of Hypertension Scientific Meeting
10. Boston Scientific Endoscopy Presents Promising Clinical Data During Digestive Disease Week ®
11. Sanofi Pasteur Presents Pediatric Data on Investigational Quadrivalent Influenza Vaccine
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/1/2014)... , Aug. 1, 2014 In the latest ... for sexual dysfunction, more than 60 doctors and leading ... open letter questioning the Food and Drug Administration,s (FDA) ... common form of male sexual dysfunction compared with ZERO ... agency to act for women by approving the first-ever ...
(Date:8/1/2014)... 2014 According to the ... Closure, Anti infective), Basic (Films, Cleansing), Advanced (Hydrogels, ... Substitutes), Pressure Relief Devices, NPWT) - Global Forecast ... Market is expected to reach $18.3 Billion by ... a CAGR of 3.2% from 2014 to 2019. ...
(Date:8/1/2014)... Inovio Pharmaceuticals, Inc. (NYSE MKT: INO) announced ... report its second quarter 2014 financial results on Monday, ... J. Joseph Kim and CFO Peter ... corporate update, and participate in a live Q&A with ... VGX-3100, Inovio,s immune therapy targeting pre-cancers and cancers associated ...
Breaking Medicine Technology:60+ Doctors and Leading Medical Experts Sign an Open Letter Urging the FDA to Approve First-Ever Drug to Treat Women's Most Common Form of Sexual Dysfunction, notes Even the Score 260+ Doctors and Leading Medical Experts Sign an Open Letter Urging the FDA to Approve First-Ever Drug to Treat Women's Most Common Form of Sexual Dysfunction, notes Even the Score 3Wound Care Market Worth $18.3 Billion by 2019 2Wound Care Market Worth $18.3 Billion by 2019 3Inovio Pharmaceuticals to Host Second Quarter 2014 Financial Results Call on August 11, 2014 2Inovio Pharmaceuticals to Host Second Quarter 2014 Financial Results Call on August 11, 2014 3
... Pharmaceutical, Inc. (OTC BB: OMBP), today issued the following letter ... of Omni Bio Pharmaceutical, Inc.: I am writing ... Executive Officer of Omni Bio Pharmaceutical, Inc., ("Omni").  With our ... appropriate juncture to update our shareholders on the basis for ...
... Biocept, Inc. today reported that its scientists and academic ... Meeting of the American Association for Cancer Research (AACR) ... poster presentations are based on studies utilizing Biocept,s novel ... tumor cell (CTCs) in human clinical samples. This technology, ...
Cached Medicine Technology:Omni Bio Pharmaceutical, Inc's. CEO Issues Letter to Shareholders 2Omni Bio Pharmaceutical, Inc's. CEO Issues Letter to Shareholders 3Omni Bio Pharmaceutical, Inc's. CEO Issues Letter to Shareholders 4Omni Bio Pharmaceutical, Inc's. CEO Issues Letter to Shareholders 5Omni Bio Pharmaceutical, Inc's. CEO Issues Letter to Shareholders 6Biocept and Academic Collaborators to Present Posters at AACR on Circulating Tumor Cells (CTCs) 2Biocept and Academic Collaborators to Present Posters at AACR on Circulating Tumor Cells (CTCs) 3Biocept and Academic Collaborators to Present Posters at AACR on Circulating Tumor Cells (CTCs) 4
(Date:8/1/2014)... Hot off the presses after the announcement of ... World’s Best Awards by Travel + Leisure , The ... Relaxation Day (technically August 15). , The Lodge at ... help guests celebrate relaxation throughout the month of August. ... wellness to carve out time to relax and unwind. ...
(Date:8/1/2014)... The "Antimicrobial Coatings Market by Type ... Titanium Dioxide, and Zinc Omadine), Application (Indoor air/HVAC, ... Beverages, Textiles, and others), & Geography (North America, ... Forecasts to 2018" analyzes the Antimicrobial Coatings Market ... in the diverse geographical regions. , Browse 49 ...
(Date:8/1/2014)... Mozes HealthDay Reporter FRIDAY, ... serve as a time-honored destination for a good cut and ... might also be the spot to tackle an often overlooked ... a novel partnership, the U.S. Centers for Disease Control and ... enlisted the help of barbershop staff to both discuss and ...
(Date:8/1/2014)... (PRWEB) August 01, 2014 According ... Market by Geography (Asia-Pacific, North America, Europe, & ... HCVs), by Fuel Type (Gasoline & Diesel), by ... Adsorber) - Trends & Forecasts to 2019", defines ... with an analysis of major countries in all ...
(Date:8/1/2014)... For years, proponents have praised breast-feeding ... study conducted by the Ohio State University, suggests ... in terms of their health and development, raising questions ... for their baby. So does this new research change ... Shapiro , chair of Pediatrics at Abington Memorial Hospital, ...
Breaking Medicine News(10 mins):Health News:The Lodge at Woodloch Kicks Off National Relaxation Day with a Month Long Celebration 2Health News:The Lodge at Woodloch Kicks Off National Relaxation Day with a Month Long Celebration 3Health News:The Lodge at Woodloch Kicks Off National Relaxation Day with a Month Long Celebration 4Health News:Antimicrobial Coatings Market Projected to Reach $2.9 Billion by 2018 – Report by MarketsandMarkets 2Health News:Antimicrobial Coatings Market Projected to Reach $2.9 Billion by 2018 – Report by MarketsandMarkets 3Health News:Antimicrobial Coatings Market Projected to Reach $2.9 Billion by 2018 – Report by MarketsandMarkets 4Health News:Barbershops Join Fight Against High Blood Pressure in Black Men 2Health News:Barbershops Join Fight Against High Blood Pressure in Black Men 3Health News:Automotive Exhaust Systems Market Will Be $33,379.7 Million by 2019 – New Report by MarketsandMarkets 2Health News:Automotive Exhaust Systems Market Will Be $33,379.7 Million by 2019 – New Report by MarketsandMarkets 3Health News:Automotive Exhaust Systems Market Will Be $33,379.7 Million by 2019 – New Report by MarketsandMarkets 4Health News:Despite Recent Study, Abington Health Expert Encourages Breastfeeding 2Health News:Despite Recent Study, Abington Health Expert Encourages Breastfeeding 3
... methods of treatment in Urogynaecology will be the focus ... on Urogynaecology and Reconstructive pelvic surgery, that begins here ... of a pelvic surgery, being conducted at Government Kasturba ... ,,Briefing reporters about the three-day conference, Dr ...
... York, June 11 An outbreak of measles in the US city ... came from India in April to work for a financial services ... the authorities are taking several steps to contain the disease which ... Globe reported. ,It claimed that the programmer who came ...
... said that the traditional-medicines sector should be recognised in ... on traditional-medicine in Benoni in which she said that ... ,Her department has already established a directorate ... allocation of money. She said that there is a ...
... launched a plan to improve the bedside manners of would-be ... students will be "embedded" with patients suffering from a chronic ... ,This program will be compulsory for the students ... in the US. "I think it would be ideal to ...
... crewmen in the early April. Followed by them two astronauts ... within 6.5 hours on Thursday. // ,In 2001, a ... for a video camera to be fixed for another was ... ,After Russians have made their decision and agreed for ...
... in a newly uncovered estrogen receptor could turn out ... vital role in signaling //other target tissues like uterus ... significantly advance the understanding of the effects of estrogen ... and potentially more effective treatments of the disease. ...
Cached Medicine News:Health News:Functional Differences In Estrogen Receptor Could Be A Therapeutic Target 2Health News:Functional Differences In Estrogen Receptor Could Be A Therapeutic Target 3
Pipetman F is a fixed-volume, air-displacement pipette. Thirteen robust models cover a large volume range from 2 L to 1000 L, with Gilsons legendary accuracy and precision....
Inquire...
... new Finnpipette Focus from Thermo ... combine ergonomics with uncompromising performance. ... plate offers a custom fit ... new shorter tip cones allow ...
Inquire...
Medicine Products: